N/A
N=80
Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Bottom Line
View on ClinicalTrials.gov: NCT04413149 ↗Enrolled (actual)
80
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Death From All Causes — 10; 5 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Peking Union Medical College Hospital
- Primary completion
- Apr 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Death From All Causes |
10; 5 | — |
| PRIMARY Number of Patients Who Underwent Lung Transplantation |
1; 0 | — |
Summary
The purpose of this study is to investigate the clinical features and long-term outcome of anti-neutrophil cytoplasmic antibody (ANCA)-positive interstitial lung disease (ILD) and assess the difference between microscopic polyangiitis (MPA) associated ILD and isolated ANCA-positive idiopathic interstitial pneumonia.
Eligibility Criteria
Inclusion Criteria
- Males and females
- Aged from 18 to 85 years with informed consent
- Have a diagnosis of ILD based on clinical symptoms and radiologic features, with or without histopathologic results
- Have available ANCA testing results during the first visit and follow-up period
Exclusion Criteria
- Connective tissue disease associated ILD
- ILD induced by drug, environment, or occupational exposure
- Hypersensitivity pneumonitis and sarcoidosis
Data sourced from ClinicalTrials.gov (NCT04413149). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.